DHTRF Stock Chart & Stats
$12.77
$0.00(0.00%)
At close: 4:00 PM EDT
$12.77
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$9.21 - $13.93
Previous CloseN/A
Volume35.00
Average Volume (3M)N/A
Market Cap
$699.51M
Enterprise Value$1.57K
Total Cash (Recent Filing)$55.16M
Total Debt (Recent Filing)$439.44M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Nov 09, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding54,973,545
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.06
Price to Sales (P/S)2.38
P/FCF Ratio-40.68
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$16.31Price Target Upside27.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)2.42
Revenue Forecast (FY)$192.24M
Bulls Say, Bears Say
Bulls Say
High-Margin Cash GenerationA 92% adjusted EBITDA margin and rising cash receipts show the royalty model can convert drug-linked revenue into substantial operating cash. If margins remain near management’s high-80s to 90% outlook, this supports distributions and reinvestment.
Royalty Portfolio GrowthRoyalty income has grown nearly 18% over two years while Q2 rose 8% year over year, indicating portfolio-level expansion rather than reliance solely on milestones. Continued growth would improve cash-flow visibility and support redeployment.
New Royalty Asset CatalystFDA approval triggered the $75M milestone and starts royalties in Q3, adding a new commercial asset to the portfolio. Expected broader access and a permanent J-code could make Lumvoa a multi-year contributor, though the ramp is not immediate.
Bears Say
Net Losses And LeverageTTM net margin is about -22%, ROE is roughly -10%, and debt-to-equity is about 1.01. This combination indicates operating strength is not yet translating into durable bottom-line returns and leaves less flexibility if royalty receipts weaken.
Product And Generic CompetitionOmidria, Spinraza and Zytiga receipts declined, with Zytiga affected by European generic entry, while Rydapt is stepping down. These pressures show product-specific competition, lifecycle effects and concentration can offset portfolio-level growth.
Portfolio Duration And Redeployment RiskThe Ekterly disposition removes a longer-duration asset and may reduce near-term receipts, making portfolio cash flows more dependent on successful redeployment. This raises execution risk because replacement assets may take time to mature and may not match prior durability.
DRI Healthcare News
DHTRF FAQ
What was DRI Healthcare’s price range in the past 12 months?
DRI Healthcare lowest stock price was $9.21 and its highest was $13.93 in the past 12 months.
What is DRI Healthcare’s market cap?
DRI Healthcare’s market cap is $699.51M.
When is DRI Healthcare’s upcoming earnings report date?
DRI Healthcare’s upcoming earnings report date is Nov 09, 2026 which is in 73 days.
How were DRI Healthcare’s earnings last quarter?
DRI Healthcare released its earnings results on Aug 07, 2026. The company reported $0.564 earnings per share for the quarter, missing the consensus estimate of $0.6 by -$0.037.
Is DRI Healthcare overvalued?
According to Wall Street analysts DRI Healthcare’s price is currently Undervalued.
Does DRI Healthcare pay dividends?
DRI Healthcare does not currently pay dividends.
What is DRI Healthcare’s EPS estimate?
DRI Healthcare’s EPS estimate is 0.76.
How many shares outstanding does DRI Healthcare have?
DRI Healthcare has 54,973,545 shares outstanding.
What happened to DRI Healthcare’s price movement after its last earnings report?
DRI Healthcare reported an EPS of $0.564 in its last earnings report, missing expectations of $0.6. Following the earnings report the stock price went up 4.157%.
Which hedge fund is a major shareholder of DRI Healthcare?
Currently, no hedge funds are holding shares in DHTRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DRI Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.11%
12-Months-Change
Fundamentals
Return on Equity
3.23%
Trailing 12-Months
Asset Growth
5.13%
Trailing 12-Months
Company Description
DRI Healthcare
DRI Healthcare Trust is an unincorporated open-ended company. It engages in the provision of differentiated exposure to the fast-growing pharmaceutical and biotechnology industries through ownership and acquisition of royalties on pharmaceutical products with a focus on delivering attractive growth in cash receipts from royalty assets over the long term. The company was founded in 1989 and is headquartered in Toronto, Canada.
DHTRF Stock 12 Month Forecast
Average Price Target
$16.31
▲(27.73% Upside)
Ownership Overview
0.54% Insiders
0.01% Mutual Funds
― Other Institutional Investors
99.03% Public Companies and
Individual Investors